Up to 50 mutations in the MAPT gene have to date been demonstrated to increase the risk of select Tauopathies, a term used to describe a group of neurodegenerative disorders characterised by Tau protein accumulation in the brain, which includes AD (Strang et al. 2019). The gene discussed is MAPT; the disease is Alzheimer disease.